Read by QxMD icon Read

European Journal of Cancer

Li-Tzong Chen, Jens T Siveke, Andrea Wang-Gillam, Chung-Pin Li, György Bodoky, Andrew P Dean, Yan-Shen Shan, Gayle S Jameson, Teresa Macarulla, Kyung-Hun Lee, David Cunningham, Jean-Frédéric Blanc, Chang-Fang Chiu, Gilberto Schwartsmann, Fadi S Braiteh, Khalid Mamlouk, Bruce Belanger, Floris A de Jong, Richard A Hubner
BACKGROUND: In the phase 3 randomised NAPOLI-1 clinical study, a 45% increase in median overall survival (OS) was shown with liposomal irinotecan, 5-fluorouracil and leucovorin (nal-IRI+5-FU/LV) versus 5-FU/LV in patients with metastatic pancreatic cancer progressing after gemcitabine-based therapy. Here, we report data from a pre-specified, expanded analysis of outcomes in the per-protocol (PP) population. MATERIALS AND METHODS: The PP population comprised patients receiving ≥80% of planned treatment during the first 6 weeks, with no major protocol violations...
November 7, 2018: European Journal of Cancer
Hao Chen, Zhaoqing Tang, Fenglin Liu
No abstract text is available yet for this article.
November 5, 2018: European Journal of Cancer
Milvia Zambetti, Filippo Montemurro, Paolo Morandi, Claudio Zamagni, Alba A Brandes, Giancarlo Bisagni, Katia Cagossi, Carmelo Bengala, Stefania Gori, Claudio Iannacone, Alessia Stell, Luca Gianni
BACKGROUND: Subcutaneous trastuzumab (H SC) is a valuable alternative to the intravenous formulation. This study assessed H SC safety and tolerability in human epidermal growth factor receptor 2 (HER2)+ early/locally advanced breast cancer (EBC/LABC). METHODS: SCHEARLY is a prospective, two-cohort, non-randomised, multicentre Italian trial included in the umbrella study UmbHER1, planning a 1-year treatment with H SC 600 mg in HER2+ EBC/LABC. Patients were sequentially assigned to cohort A (N = 121) and B (N = 119) to receive H SC via a handheld syringe and a single-use injection device, respectively...
November 2, 2018: European Journal of Cancer
Jun Hamano, Ayano Takeuchi, Takuhiro Yamaguchi, Mika Baba, Kengo Imai, Masayuki Ikenaga, Yoshihisa Matsumoto, Ryuichi Sekine, Takashi Yamaguchi, Takeshi Hirohashi, Tsukasa Tajima, Ryohei Tatara, Hiroaki Watanabe, Hiroyuki Otani, Hiroka Nagaoka, Masanori Mori, Yo Tei, Shuji Hiramoto, Tatsuya Morita
INTRODUCTION: There have been no reports about predicting survival of patients with advanced cancer constructed entirely with objective variables. We aimed to develop a prognostic model based on laboratory findings and vital signs using a fractional polynomial (FP) model. METHODS: A multicentre prospective cohort study was conducted at 58 specialist palliative care services in Japan from September 2012 to April 2014. Eligible patients were older than 20 years and had advanced cancer...
November 1, 2018: European Journal of Cancer
Hiroshi Saeki, Eiji Oki, Tomomi Kashiwada, Takaaki Arigami, Akitaka Makiyama, Masaaki Iwatsuki, Yukiya Narita, Hironaga Satake, Yoshiko Matsuda, Hideto Sonoda, Mototsugu Shimokawa, Yoshihiko Maehara
BACKGROUND: Anti-HER2 therapy has not demonstrated a survival advantage in the second-line setting of patients with HER2-positive gastric cancer. We conducted this study to assess changes in HER2 status and to identify possible biomarkers for acquired resistance after the use of trastuzumab as the first-line therapy. PATIENTS AND METHODS: Patients with advanced or recurrent HER2-positive gastric adenocarcinoma who were diagnosed with progressive disease after the first-line trastuzumab-based therapy and developed pathologically confirmed adenocarcinoma within 3 months after completion of trastuzumab-based therapy were enrolled in this study...
November 1, 2018: European Journal of Cancer
L Kandolf Sekulovic, J Guo, S Agarwala, A Hauschild, G McArthur, G Cinat, A Wainstein, C Caglevic, P Lorigan, H Gogas, M Alvarez, R Duncombe, C Lebbe, K Peris, P Rutkowski, A Stratigos, A-M Forsea, L De La Cruz Merino, M Kukushkina, R Dummer, C Hoeller, C Gorry, L Bastholt, D Herceg, B Neyns, R Vieira, P Arenberger, M Bylaite-Bucinskiene, N Babovic, M Banjin, K Putnik, V Todorovic, K Kirov, J Ocvirk, A Zhukavets, A Ymeri, I Stojkovski, C Garbe
According to data from recent studies from Europe, a large percentage of patients have restricted access to innovative medicines for metastatic melanoma. Melanoma World Society and European Association of Dermato-oncology conducted a Web-based survey on access to first-line recommended treatments for metastatic melanoma by current guidelines (National Comprehensive Center Network, European Society for Medical Oncology [ESMO] and European Organization for Research and Treatment of Cancer/European Association of Dermato-oncology/European dermatology Forum) among melanoma experts from 27 European countries, USA, China, Australia, Argentina, Brazil, Chile and Mexico from September 1st, 2017 to July 1st, 2018...
October 30, 2018: European Journal of Cancer
Elie El Rassy, Hussein Khaled, Nicholas Pavlidis
Cancer of unknown primary (CUP) is a heterogeneous group of metastatic cancers characterised by early dissemination of metastases in the absence of any identifiable primary site. Most patients with CUP have poor prognosis with the traditional diagnostic and treatment modalities. Recognising the putative primary tumour is hypothesised to ameliorate the prognosis of patients with CUP by guiding treatment decisions. The active efforts in molecular oncology have shown that gene expression profiling is able to identify the primary tumour site and to determine targetable mutations...
October 30, 2018: European Journal of Cancer
Jasmina Mallet, Olivier Huillard, Francois Goldwasser, Caroline Dubertret, Yann Le Strat
BACKGROUND: Receiving a diagnosis of cancer may be associated with increased risk of mental disorders. Yet, in this context, no factor predicts the onset of a mental disorder besides the diagnosis of cancer itself. If patients with a history of mental disorder are at particular risk is unknown. METHODS: Data were derived from a large national sample of the US population. Face-to-face surveys were conducted on 36309 adults during 2012-2013 period. Data were used to examine the associations among the past-year prevalence of mental disorders (according to the Diagnostic and Statistical Manual of Mental Disorders-5), the treatment-seeking rates and a recent cancer diagnosis...
October 30, 2018: European Journal of Cancer
M Kandel, C Allayous, S Dalle, L Mortier, S Dalac, C Dutriaux, M T Leccia, B Guillot, P Saiag, J P Lacour, D Legoupil, T Lesimple, F Aubin, M Beylot-Barry, F Brunet-Possenti, J P Arnault, F Granel-Brocard, P E Stoebner, A Dupuy, E Maubec, J J Grob, B Dreno, F Rotolo, A Ballon, S Michiels, C Lebbe, I Borget
PURPOSE: Since 2011, significant progress was observed in metastatic melanoma (MM), with the commercialisation of seven immunotherapies or targeted therapies, which showed significant improvement in survival. In France, in 2004, the cost of MM was estimated at €1634 per patient; this cost has not been re-estimated since. This study provided an update on survival and cost in real-life clinical practice. METHODS: Clinical and economic data (treatments, hospitalisations, radiotherapy sessions, visits, imaging and biological exams) were extracted from the prospective MelBase cohort, collecting individual data in 955 patients in 26 hospitals, from diagnosis of metastatic disease until death...
October 29, 2018: European Journal of Cancer
Dario Callegaro, Rosalba Miceli, Sylvie Bonvalot, Peter Ferguson, Dirk C Strauss, Antonin Levy, Anthony Griffin, Andrew J Hayes, Silvia Stacchiotti, Cecile Le Pèchoux, Myles J Smith, Marco Fiore, Angelo Paolo Dei Tos, Henry G Smith, Charles Catton, Paolo G Casali, Jay S Wunder, Alessandro Gronchi
BACKGROUND: The role of radiotherapy (RTx) and chemotherapy (CTx) in primary extremity soft tissue sarcoma (eSTS) patients is not precisely defined. METHODS: All consecutive primary eSTS patients treated within three European and one North American reference centres in a 20-year time span were included. The tendency to perform chemotherapy/radiotherapy (CTx/RTx) was explored using multivariable binary logistic models. Five and 10-year overall survival (OS) and crude cumulative incidence (CCI) of local recurrence (LR) and distant metastasis (DM) were estimated...
October 29, 2018: European Journal of Cancer
Mairéad Geraldine McNamara, Astrid E Slagter, Christina Nuttall, Melissa Frizziero, Rille Pihlak, Angela Lamarca, Noor Tariq, Juan W Valle, Richard A Hubner, Jennifer J Knox, Eitan Amir
BACKGROUND: Sorafenib has demonstrated survival benefit in first-line treatment of advanced hepatocellular carcinoma (HCC); utility of sorafenib in patients with advanced HCC and Child-Pugh B (CP-B) liver function remains a subject of debate. METHODS: A systematic review identified studies using first-line sorafenib in patients with advanced HCC and CP-A/B liver function. Meta-regression analysis comprising linear regression was conducted to explore the association between the baseline factors and overall survival (OS)...
October 29, 2018: European Journal of Cancer
Serge Evrard, Guido Torzilli, Carmela Caballero, Benjamin Bonhomme
The treatment of advanced colorectal liver metastases (CRLMs) follows the biphasic pattern characteristic of oncological surgery. A phase of escalation-the therapeutic aggressiveness-is followed by a phase of de-escalation aimed at decreasing the morbidity, while preserving the gains in survival. From a maximum of three lesions, the rule no longer limits the number, provided the intervention does not cause lethal liver failure. Technically feasible non-anatomical resections, two-stage hepatectomies, portal vein obliteration and so forth, have pushed the boundaries of surgery far...
October 28, 2018: European Journal of Cancer
Matthew T Campbell, Mehmet A Bilen, Amishi Y Shah, Emily Lemke, E Jonasch, A M Venkatesan, E Altinmakas, C Duran, Pavlos Msaouel, N M Tannir
BACKGROUND: Cabozantinib prolongs overall survival (OS) and progression-free survival (PFS) in patients with metastatic clear cell renal cell carcinoma (RCC) that progressed on first-line vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI). The role of cabozantinib has not been established in non-clear cell renal cell carcinoma (nccRCC). METHODS: This is a retrospective study of 30 patients with nccRCC who received cabozantinib from January 2013 to January 2017...
October 28, 2018: European Journal of Cancer
N Tshuma, N Glynn, J Evanson, T Powles, W M Drake
No abstract text is available yet for this article.
October 27, 2018: European Journal of Cancer
Dirk H Wijn, Geert H Groeneveld, Albert M Vollaard, Mirte Muller, Jacco Wallinga, Hans Gelderblom, Egbert F Smit
BACKGROUND: Influenza vaccination is recommended in patients with cancer to reduce influenza-related complications. Recently, more immune-related adverse events (irAEs) were demonstrated in patients with lung cancer who were vaccinated with the trivalent seasonal influenza vaccine during anti-programmed death receptor 1 (PD-1) immunotherapy. Confirmation of these findings is essential before recommendations on influenza vaccination may be revoked. METHODS: In this cohort study in patients with lung cancer receiving nivolumab 3 mg/kg every 2 weeks during two influenza seasons (2015/16-2016/17), irAEs have been monitored...
October 24, 2018: European Journal of Cancer
Joseph M Connors, John Radford
No abstract text is available yet for this article.
October 22, 2018: European Journal of Cancer
Jammbe Z Musoro, Andrew Bottomley, Corneel Coens, Alexander Mm Eggermont, Madeleine T King, Kim Cocks, Mirjam Ag Sprangers, Mogens Groenvold, Galina Velikova, Hans-Henning Flechtner, Yvonne Brandberg
INTRODUCTION: Health-related quality of life (HRQOL) is increasingly recognised as an important end-point in cancer clinical trials. The concept of minimally important difference (MID) enables interpreting differences and changes in HRQOL scores in terms of clinical meaningfulness. We aimed to estimate MIDs for interpreting group-level change of European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 (EORTC QLQ-C30) scores in patients with malignant melanoma...
October 22, 2018: European Journal of Cancer
S A Hurvitz, R G W Quek, N C Turner, M L Telli, H S Rugo, A Mailliez, J Ettl, E Grischke, L A Mina, J Balmaña, P A Fasching, H Bhattacharyya, A L Hannah, M E Robson, A M Wardley
BACKGROUND: Talazoparib (1 mg/day) exhibited promising efficacy and safety in patients with advanced breast cancer during ABRAZO (NCT02034916); this study evaluated patient-reported outcomes (PROs). PATIENTS AND METHODS: ABRAZO is a two-cohort, two-stage, phase 2 study of talazoparib in patients with advanced breast cancer after a response to prior platinum-based therapy (cohort 1 [C1], n = 49) or ≥3 platinum-free cytotoxic-based regimens (cohort 2 [C2], n = 35)...
October 22, 2018: European Journal of Cancer
R Zanetti, L Sacchetto, J W Coebergh, S Rosso
The availability of population-based cancer registry (CR) data is paramount in the development of modern oncology. Major contributions consisted in accurately measuring cancer burden (incidence, survival and prevalence, beside mortality), identifying and quantifying risk factors (case control and cohort studies that, in the last two decades, included gene variant assessment) and evaluating outcomes of treatments and preventive interventions, including mass screening. Cancer registration coverage of European populations progressed slowly since 1940 and is now almost 50%...
October 20, 2018: European Journal of Cancer
Dieuwertje E Kok, Renate M Winkels, Carla Ml van Herpen, Ellen Kampman
Severe treatment-induced toxicities can have clinical consequences such as hospitalisation or treatment modifications, which in turn may deteriorate the prognosis of patients with cancer. Identification of determinants of treatment-induced toxicities is essential to develop strategies that promote therapy compliance and enhance the quality of life. Whereas toxicities are systematically recorded and graded per protocol in most clinical trials, observational studies often depend on retrospective data collection from medical records collected as standard care...
October 20, 2018: European Journal of Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"